Showing results (671-680 of 1,122) with videos related to

Sort By:
Pageof 113
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 1992
Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group studyR M Bukowski, C Tangen, R Lee, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 1, 1994
Amifostine: potential for clinically useful cytoprotectionG T Budd, V Lorenzi, R Ganapathi, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2007
Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinomaSaby George, Thomas E Hutson, Tarek Mekhail, et al.
The Annals of Thoracic Surgery|March 1, 2005
Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma?Sudish C Murthy, Kwhanmien Kim, Thomas W Rice, et al.
The Journal of Rheumatology|August 16, 2015
Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial SpondyloarthritisMaxime Dougados, Wen-Chan Tsai, Diego L Saaibi, et al.
Chemsuschem|May 21, 2026
Reaction Pathways in the (De)hydrogenation of N-Heterocyclic Liquid Hydrogen Carriers Over Supported Pd CatalystsMatthew D Edgar, Fujie Lan, Sara Ahsan, et al.
Seminars in Arthritis and Rheumatism|December 24, 2014
The burden of non-radiographic axial spondyloarthritisAnnelies Boonen, Joachim Sieper, Désirée van der Heijde, et al.
The Journal of Urology|November 13, 2007
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapyIla Tamaskar, Jorge A Garcia, Paul Elson, et al.
Blood|March 26, 1999
Downregulation of JAK3 protein levels in T lymphocytes by prostaglandin E2 and other cyclic adenosine monophosphate-elevating agents: impact on interleukin-2 receptor signaling pathwayV Kolenko, P Rayman, B Roy, et al.
Investigational New Drugs|August 17, 2010
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinomaDale R Shepard, Matthew M Cooney, Paul Elson, et al.
Pageof 113